The Rheumatoid Patient Foundation is pleased to announce our new partnership with Scipher Medicine. Our mission is to improve the lives of people with Rheumatoid Disease (PRD) and Scipher Medicine is working to do just that with their belief that patients deserve answers to their treatment options using scientifically backed data. They are currently working to develop a simple blood test, PrismRA, that could identify patients who do not respond to anti-TNF therapies.
As those of us with rheumatoid disease know all too well, sometimes the prescription authorization process requires a sequence of medications, typically starting with biologics in the anti-TNF category. And sometimes, even after having been on multiple drugs in that category, a patient may have to try yet another before being approved for a newer therapy, but that’s a blog post of its own. So why are we so excited about what Scipher Medicine is working on?
With the development of this blood test, patients may be able to skip a class of drugs that would be ineffective for them, allowing them to begin other treatment options sooner. Imagine the impact innovation like this could have on PRD! If we could identify non-responders to TNF inhibitors, there is the potential for patients to get on a drug that works sooner and that could mean less damage, disability, and slowed disease progression. In the absence of a cure, these are critical factors.
The RPF and Scipher Medicine know that the "average" RD patient doesn’t exist and neither should the average treatment plan. We are excited to partner with Scipher Medicine as they work to give these non-responsive patients faster access to alternative approved targeted therapies and save them time and the damage caused while on ineffective drugs.
If you would like to help Scipher Medicine's efforts, sign up for NETWORK-004, the trial for PrismRA at ScipherMedicine.com/Trials. You will enter your name and the state you live in and then be shown a list of participating clinic sites. The site list is constantly being updated, so if you don’t see a participating site near you, don’t forget to check back soon. Your involvement now, could improve the life of many patients in the future.
What can you expect if eligible for the study? The study for PrismRA requires no investigational drug; it simply follows you as you progress through your ongoing treatment with the addition of a few small blood tests. You would visit the clinic and provide a few small blood samples as you continue your care with your physician. Full criteria to participate is on the link above. In short, you must meet the following criteria:
- 18 or older with moderate to severe RA/RD
- have been on Methotrexate for at least 12 weeks
- have never previously taken an anti-TNF
- Be willing to take an anti-TNF
The Rheumatoid Patient Foundation is committed to improving the lives of people with Rheumatoid Disease and is grateful for other organizations like Scipher Medicine to be with us in the fight. For more information on Scipher Medicine, visit ScipherMedicine.com.
About Scipher Medicine
Scipher MedicineTM holds a fundamental conviction that patients with autoimmune diseases deserve a simple answer to their treatment options using scientifically-backed data. The company’s mission is to get patients the right drug from day one by developing tests that predict non-response to targeted therapies, starting with rheumatoid arthritis. Scipher’s PrismRATM is a simple blood test, currently in a clinical trial, that identifies patients who won’t respond to anti-TNFs before starting their first biologic therapy, potentially giving these patients access to alternative approved targeted therapies sooner. Many RA patients take anti-TNF therapies, yet most of them do not respond adequately. Scipher is determined to find these patients and get them the right drug from day one. To learn more, visit www.sciphermedicine.com.